Crowell Talks Tax: IRA and Tax Exempt Entities (VIDEO)
Client Alert | 11 min read | 04.09.24
Tax partner Carina Federico and Tax counsel Eleanor Moran McWaters discuss IRA and Tax Exempt Entities.
Key Takeaways:
- Changes that affected tax exempt organizations
- How tax-exempt organizations can take advantage of the IRA
- Understanding “elective pay” or “direct pay” and who qualifies
- Issues that tax-exempt organizations should consider
Previous Videos:
Crowell Talks Tax
IRA and Tax Exempt Entities
Crowell Talks Tax
IRA and Tax Exempt Entities
Contacts
Partner
She/Her/Hers
Insights
Client Alert | 4 min read | 04.10.25
Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”
In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
Client Alert | 1 min read | 04.09.25
Client Alert | 12 min read | 04.09.25
Client Alert | 4 min read | 04.07.25
